Industry news

Physicians want better information sharing with biopharmaceutical companies

Mit Spears / PhRMA

The issue and debate around communications with health care professionals is at its very essence, a conversation about ensuring physicians have the best possible data to effectively treat patients. In an op-ed published in Morning Consult, Dr. R. Doyle Stulting, co-founder of the Stulting Research Center and the Director of Corneal Disease & Research at Woolfson Eye Institute noted FDA’s outdated regulations in this space and how sharing the latest information, which can improve patient outcomes, has become an increasingly burdensome venture [for manufacturers]. 

Top cancer doc takes to social media to fight rising prices

Emily Wasserman / FiercePharmaMarketing

The drug pricing debate has reached a pinnacle as of late, with lawmakers, presidential hopefuls and payers railing against skyrocketing costs. Back in February, when the noise was more of a dull roar, a top cancer doctor joined the growing chorus of discontent, announcing that he would protest cancer drug prices on social media.

U.K. commits a further $375M to 100,000 Genomes Project

Nick Paul Taylor / Fierce Biotech IT

The United Kingdom has committed a further $375 million to its massive sequencing initiative, the 100,000 Genomes Project. Government officials are making the extra cash available to finance the introduction of whole-genome sequencing into the National Health Service (NHS).

FDA Addresses Industry Concerns with Quality Metrics

Jill Wechsler / BioPharm International

Agency officials are emphasizing that new quality metrics data will be just one factor that FDA uses to assess a facility and drug products, seeking to address industry concerns that providing FDA with specific information on production shortcomings could lead to public criticism and enforcement action. 

The 25 most influential people in biopharma in 2015

John Carroll / FierceBiotech

A lot of people make news in the biopharma business. Few of them are influential. Influence, simply put, is the ability to make your mark in such a way as to get other prominent people in this business to rethink the way they do business.

Beijing aims to refill medicine chest with "Made in China" drugs

Ben Hirschler and Adam Jourdan / Reuters

China, already a global powerhouse in high-tech areas from solar panels to bullet trains, is turning its industrial might to the challenge of making more of its own drugs for a vast and ageing population.

26 November 2015

Epigenetics Drugs and Diagnostic Technologies Market is to reach US$5.7 billion by 2018 - Transparency Market Research

Industry Today

Epigenetics deals with the study of gene expression without altering the gene sequence. The epigenetic change associated with gene expression happens with the modification of the transcription mechanism. The key components that are involved in the regulation of epigenetic transcription are DNA methylation, micro RNA, histone modifications, and non-coding RNA’s.

Reporting, data security & deal flow management: 2015 GP survey results

PitchBook Dealmakers Column

In the past few years, the debate around transparency in the alternative investment industry has intensified. For both limited partners and general partners, the proper management and dispersion of correct information is likely the paramount concern. There is plenty of concern around information sharing both internally and externally with investors and portfolio companies. 

If TV's everywhere, then where does pharma need to be?

Tracy Staton / Fierce Pharma Marketing

Good-bye appointment TV, hello TV everywhere. As TV and video watching becomes wherever and whenever consumers want, marketers, including pharma, have had to shift strategies to reach those hard-to-pin-down viewers.

Scientists make strides with real-time estrogen sensor

Emily Wasserman / FierceMedicalDevices

As scientists develop next-generation sensors to facilitate patient monitoring, researchers in New Zealand are rolling out a sensor device that can detect estrogen levels without some of the setbacks of current technology.